An endogenous C-terminal decapeptide that acts as the primary neuroendocrine gatekeeper of gonadotropin-releasing hormone (GnRH) and reproductive axis signaling.
~4 - 10 minutes
KISS1R (GPR54) Receptor
C63H83N17O14
Investigated in clinical research protocols via intravenous infusion and subcutaneous administration.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Kisspeptin-10: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C63H83N17O14
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Kisspeptin-10 is the minimal biologically active sequence derived from the cleavage of preprokisspeptin (encoded by the KISS1 metastasis-suppressor gene). Discovered to be central to reproductive endocrinology, kisspeptin neurons in the hypothalamus synapse directly onto GnRH neurons, serving as the master regulatory switch for luteinizing hormone (LH) and follicle-stimulating hormone (FSH) pulsatility.
Potently activates the G-protein coupled receptor GPR54 (KISS1R) on hypothalamic GnRH neurons, driving intracellular Gq/11-coupled calcium release that triggers GnRH release without causing direct pituitary receptor exhaustion.
Peer-reviewed publications, clinical trials, and preclinical research investigating Kisspeptin-10.
Clinical endocrine study establishing that intravenous kisspeptin-10 administration rapidly stimulates hypothalamic GnRH and pituitary LH secretion without downstream endocrine receptor exhaustion.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Investigated in clinical research protocols via intravenous infusion and subcutaneous administration.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
